ERBB2 and metastatic neoplasm: In light of a high cumulative incidence of BRM and comparatively low risk of death, patients with ERBB2-positive MBC may be ideal candidates for BRM screening, particularly in the setting of systemic therapies with known CNS efficacy31,32,39,40,41 and survival benefits that extend to patients with active BRM.42 Further, given an almost linear increase in incidence of BRM for at least 5 years after a MBC diagnosis, ongoing long-term screening for intracranial metastatic disease may be indicated among patients with ERBB2-positive MBC.